Bristol-Myers’ checkpoint star Opdivo fails a PhIII study for glioblastoma
Their big drug Opdivo failed to beat out Avastin in treating recurrent glioblastoma, or brain cancer, in improving overall survival rates. Investigators are holding back the actual data for a presentation at an upcoming conference in Zurich.
Checkmate-143 was the first randomized study of a PD-1 checkpoint for glioblastoma, says Bristol-Myers, which is still pursuing two first-line GBM clinical trials, CheckMate -498 and CheckMate -548, evaluating the combination of Opdivo with radiation therapy with or without temozolomide in O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated and methylated patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.